CSL Limited To Apply For License To Market Influenza Vaccine In The U.S.

NEW YORK--(BUSINESS WIRE)--Feb. 7, 2006--CSL Limited (ASX: CSL), a global, specialty biopharmaceutical company headquartered in Melbourne, Australia, today announced plans to introduce its influenza vaccine into the U.S. market. Speaking at Merrill Lynch's Global Pharmaceutical and Biotechnology Conference here, CSL Chief Executive Officer and Managing Director Dr. Brian McNamee said, "CSL is the leading producer of influenza vaccine in the Southern Hemisphere and has a long heritage in biological research and manufacture. With the planned expansion of our influenza vaccine production capabilities, we look forward to working with the Food and Drug Administration (FDA) on the licensing of our vaccine in the U.S."